01—Abstract
Summary
Summary of the 10-Q filed April 24, 2024. Cited figures are marked; the original filing is the authoritative source.
Biogen Inc. (BIIB) reported a decrease in total revenue for the first quarter of 2024, down 7.0% year-over-year to $2.29 billiona.
This decline was primarily driven by a significant drop in contract manufacturing, royalty, and other revenue, which fell 38.5% to $184.6 millionb. Product revenue also saw a modest decrease of 2.9% to $1.71 billion, largely due to ongoing generic competition impacting Multiple Sclerosis (MS) revenues, which decreased by 4.4%, and a decrease in Rare Disease revenue by 4.4%.
Despite the revenue challenges, the company managed to increase its net income to $393.4 millionc, a slight rise from $387.9 million in the prior year's quarter, resulting in diluted earnings per share of $2.70, up from $2.67. The company also demonstrated strong operational cash flow generation of $553.2 million.
02—Key points
Key Highlights
- Total revenue declined 7.0% to $2.29 billion in Q1 2024, mainly due to lower contract manufacturing, royalty, and other revenue.
- Product revenue decreased by 2.9% to $1.71 billion, impacted by generic competition in the Multiple Sclerosis (MS) segment.
- Multiple Sclerosis (MS) revenue decreased by 4.4% ($49.3 million) due to generic competition for TECFIDERA and ongoing patient shifts to higher efficacy therapies.
- Rare Disease revenue decreased by 4.4% ($19.4 million), primarily due to timing of SPINRAZA shipments outside the U.S. and modest impacts from competition and foreign currency exchange.
- Net income attributable to Biogen Inc. increased slightly by 1.5% to $393.4 million.
- Diluted earnings per share (EPS) increased to $2.70 from $2.67 in the prior year's quarter.
- Operating cash flow remained robust at $553.2 million, an increase from $455.3 million in Q1 2023.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed April 24, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $2.29B$2.46B | −7.0% |
| Cost of Revenue | $542.20M$662.80M | −18.2% |
| Gross Profit | $1.75B$1.80B | −2.9% |
| SG&A Expenses | $581.50M$605.00M | −3.9% |
| Operating Expenses | $1.83B$2.02B | −9.8% |
| Interest Expense | $69.20M$62.50M | +10.7% |
| Net Income | $393.40M$387.90M | +1.4% |
| EPS (Basic) | $2.71$2.69 | +0.7% |
| EPS (Diluted) | $2.70$2.67 | +1.1% |
| Shares Outstanding (Basic) | 145.20M144.40M | +0.6% |
| Shares Outstanding (Diluted) | 145.90M145.20M | +0.5% |
05—Questions
Frequently Asked Questions
What is the primary driver behind the decrease in Biogen's total revenue?
The primary driver for the 7.0% decrease in total revenue for Q1 2024 was a significant decline in 'Contract manufacturing, royalty and other revenue,' which fell by 38.5%. This was partly offset by a smaller decrease in 'Product revenue' and 'Revenue from anti-CD20 therapeutic programs'.
How is the Multiple Sclerosis (MS) business performing, and what are the main challenges?
MS revenue decreased by 4.4% ($49.3 million). This decline is primarily attributed to the impact of generic entrants for TECFIDERA in key markets and patients transitioning to newer, more effective therapies for other MS products. The company also noted the entrance of a TYSABRI biosimilar in the U.S. and EU as a future concern.
What is the contribution of SKYCLARYS to Biogen's revenue, and what is its market status?
SKYCLARYS, acquired through the Reata acquisition, contributed $78.0 million in global revenue in Q1 2024, with $73.0 million from the U.S. and $5.0 million from the EU, where it received approval in February 2024. The company expects continued growth for SKYCLARYS.
Has Biogen made any significant debt repayments during the quarter?
Yes, Biogen repaid $400.0 million of its 2023 Term Loan during the first quarter of 2024, with $150.0 million related to the 364-day tranche and $250.0 million related to the three-year tranche. This resulted in a decrease in total borrowings.
06—Continue